Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer

Oncology Reports

Volumn 8, Issue 5, 2001, Pages 1171-1176

  Kim, Ryungsa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

HER 2; Paclitaxel; Pharmacokinetics; Relapsed breast cancer; Weekly 1 h infusion

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BREAST TUMOR; DRUG ADMINISTRATION; DRUG RESISTANCE; FEASIBILITY STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 0035458870     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.5.1171     Document Type: Article

References (2)

1. Scidman AD: Single-agent paxlitaxel in the treatment of breast cancer: phase I and II development. Semin Oncol 26 (Suppl 8): 14-20, 1999.
2. Di Leo A and Piccart MJ: Paclitaxcl activity, dose and schedule: data from phase II/I trials in metastatic breast cancer. Semin Oncol 26 (Suppl 8): 27-32, 1999.